Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
View forecast on Grants.gov →Forecasted — not yet open
- Posted
- July 14, 2026
- Closes
- See announcement
- Award ceiling
- $300,000
- Program funding
- $6,600,000
- Expected awards
- 14
- Cost sharing
- No
- Instrument
- Grant
- Assistance listing
- 93.394
- Category
- Health
Program funding history
Awards made under Assistance Listing 93.394 across FY2025–FY2027, from public federal spending records.
- FY2025 obligated
- $595.6M
- FY2026 obligated
- $548.5M
- FY2027 (to date) obligated
- $0
- Awards in window
- 1,877
Top recipients: Regents of the University of California, San Francisco, the, Fred Hutchinson Cancer Center, The Johns Hopkins University, The Leland Stanford Junior University, The Univeristy of Texas M.d. Anderson Cancer Center
Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies for cancer research or clinical care. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development, enhancements, optimizations, and rigorous technical validation to encourage adoption by the research community.
Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications. Projects proposing application of existing technologies where the novelty resides in the clinical target or biological question being pursued are not appropriate for this solicitation.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Who can apply
- Public and State controlled institutions of higher education
- Independent school districts
- County governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Special district governments
- State governments
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Public housing authorities/Indian housing authorities
- Small businesses
- City or township governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- For profit organizations other than small businesses
- Native American tribal governments (Federally recognized)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
How to apply
Applications go through the official government listing. Grants Radar links you straight to the source — applying is free.
New to federal funding? How to read an announcement · Who can apply · How grants work
Tell me when this program posts again
One email the morning after this program opens for applications — under this number or a new one — and one more about a week before it closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.
Similar grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
Same-day alerts, matched to you
The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.
Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.
See pricing